<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771641</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-9003</org_study_id>
    <secondary_id>CDR0000076475</secondary_id>
    <nct_id>NCT00771641</nct_id>
  </id_info>
  <brief_title>Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>Phase III Randomized Comparison of Radiotherapy Fractionation in Advanced Squamous Cell Carcinoma of the Head and Neck: Twice-Daily Hyperfractionation vs Split-Course Accelerated Hyperfractionation vs Accelerated Fractionation With Concomitant Boost vs Standard Fractionation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Patient abstract not available

      PURPOSE: Patient abstract not available
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether hyperfractionation and/or accelerated fractionation
      (split-course or with a concomitant boost) improves the locoregional control rate over
      standard fractionation radiotherapy in patients with advanced squamous cell carcinomas of the
      head and neck. II. Determine the disease-free survival and overall survival of these patients
      treated with different radiotherapy fractionation schemes. III. Determine the acute and late
      toxicities of each fractionation schedule. IV. Compare the quality of life on the two
      regimens.

      OUTLINE: Randomized study. Arm I: Radiotherapy. Irradiation of primary tumor and involved and
      at-risk nodal areas using linear accelerators with photon energies of 1.25-6.0 MV (dual
      energy arrangements may also use a beam greater than 6.0 MV), electrons of 4-25 MV, or Co60.
      Standard fractionation. Arm II: Radiotherapy. Targets and equipment as in Arm I.
      Hyperfractionation. Arm III: Radiotherapy. Targets and equipment as in Arm I. Accelerated
      split-course hyperfractionation. Arm IV: Radiotherapy. Targets and equipment as in Arm I.
      Accelerated fractionation with concomitant boost.

      PROJECTED ACCRUAL: A total of 1,080 patients (270/arm) will be accrued over 5.75 years. If
      excessive toxicity is noted in any arm after entry of 324 and 634 patients, that arm may be
      closed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1113</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperfractionation: 1.2 Gy/Fx, b.i.d. (&gt; 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated Hyperfractionation with split</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (&gt; 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated fractionation with concomitant boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated fractionation with concomitant boost</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_label>Accelerated Hyperfractionation with split</arm_group_label>
    <arm_group_label>Accelerated fractionation with concomitant boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET cobalt-60 gamma ray therapy</intervention_name>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_label>Accelerated Hyperfractionation with split</arm_group_label>
    <arm_group_label>Accelerated fractionation with concomitant boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET electron therapy</intervention_name>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_label>Accelerated Hyperfractionation with split</arm_group_label>
    <arm_group_label>Accelerated fractionation with concomitant boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_label>Accelerated Hyperfractionation with split</arm_group_label>
    <arm_group_label>Accelerated fractionation with concomitant boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_label>Accelerated Hyperfractionation with split</arm_group_label>
    <arm_group_label>Accelerated fractionation with concomitant boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and
        neck, including lymphoepithelioma and anaplastic carcinoma Biopsy from the primary or
        regional nodes acceptable No adenocarcinomas The following stages and sites are eligible:
        Stage III/IV oral cavity, including: Anterior 2/3 of the tongue Buccal mucosa Floor of
        mouth Hard palate Gingiva Retromolar trigone Stage III/IV oropharynx, including: Tonsil and
        pillars Faucial arch and soft palate Posterolateral pharyngeal walls Stage II/III/IV base
        of the tongue and hypopharynx Stage III/IV supraglottic larynx, including: Ventricular band
        Arytenoid Supra- and infrahyoid epiglottis Aryepiglottic fold (tumors at glottic and
        subglottic sites excluded) Nonpalpable nodes detected only on CT or MRI must be at least
        1.0 cm in diameter or contain necrosis to prove N+ disease No metastasis below the clavicle
        clinically or radiologically

        PATIENT CHARACTERISTICS: Age: At least 18 Performance status: Karnofsky 60-100%
        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Medically
        able to withstand radiotherapy No second malignancy within 5 years except nonmelanomatous
        skin cancer Follow-up by participating radiotherapist required

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head
        and neck No planned combined external beam and interstitial boost irradiation Surgery: No
        prior surgery (other than biopsy) No planned combined pre- or postoperative programs
        Radical neck dissections allowed if lymph nodes are greater than 3 cm prior to radiotherapy
        or involvement persists after treatment Resection of persistent disease at the primary site
        may be performed 6 weeks after completion of radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. Kian Ang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <reference>
    <citation>Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012 Jun 10;30(17):2102-11. doi: 10.1200/JCO.2011.38.4099. Epub 2012 May 7.</citation>
    <PMID>22565003</PMID>
  </reference>
  <reference>
    <citation>Dilling TJ, Bae K, Paulus R, Watkins-Bruner D, Garden AS, Forastiere A, Kian Ang K, Movsas B. Impact of gender, partner status, and race on locoregional failure and overall survival in head and neck cancer patients in three radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e101-9. doi: 10.1016/j.ijrobp.2011.01.013. Epub 2011 May 5.</citation>
    <PMID>21549515</PMID>
  </reference>
  <reference>
    <citation>Spiegel D, Kraemer HC. Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study. Cancer. 2008 May 15;112(10):2326-7; author reply 2327-8. doi: 10.1002/cncr.23435.</citation>
    <PMID>18338746</PMID>
  </reference>
  <reference>
    <citation>Cullen KJ, Nikitakis N, Goloubeva O, et al.: Effect of elevated expression of GST-Ï€ and p53 on prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone: An analysis of RTOG trials 9003 and 9501. [Abstract] J Clin Oncol 26 (Suppl 15): A-6013, 2008.</citation>
  </reference>
  <reference>
    <citation>Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res. 2008 Sep 15;14(18):5877-83. doi: 10.1158/1078-0432.CCR-08-0998.</citation>
    <PMID>18794100</PMID>
  </reference>
  <reference>
    <citation>Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):353-60. Epub 2007 Sep 24.</citation>
    <PMID>17889449</PMID>
  </reference>
  <reference>
    <citation>Coyne JC, Pajak TF, Harris J, Konski A, Movsas B, Ang K, Watkins Bruner D; Radiation Therapy Oncology Group. Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study. Cancer. 2007 Dec 1;110(11):2568-75.</citation>
    <PMID>17955501</PMID>
  </reference>
  <reference>
    <citation>Sanabria A, Carvalho AL, Kowalski LP. Is nutrition support related to a poor prognosis in head and neck cancer patients? Thoughts about the secondary analysis of RTOG trial 90-03. Head Neck. 2007 May;29(5):518-9; author reply 519-20.</citation>
    <PMID>17390379</PMID>
  </reference>
  <reference>
    <citation>Konski AA, Pajak T, Movsas B, et al.: Socio-demographic variables influence outcome in Radiation Therapy Oncology Group head and neck trials. [Abstract] Proceedings of the American Society of Clinical Oncology 22 (Suppl 14): A-6043, 529s, 2004.</citation>
  </reference>
  <reference>
    <citation>Kumar P, Harris J, Garden AS, et al.: Outcome comparisons of four Radiation Therapy Oncology Group (RTOG) trials in patients with stage IV-T4 head and neck (H/N) cancer: encouraging results using intra-arterial (IA) cisplatin (P) and concurrent radiation therapy (RT). [Abstract] J Clin Oncol 22 (Suppl 14): A-5527, 494s, 2004.</citation>
  </reference>
  <reference>
    <citation>Movsas B, Konski A, Pajak T, et al.: Quality of life (QOL) variables influence local regional control in Radiation Therapy Oncology Group (RTOG) headsneck trials (9003 and 9111). [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-199, S252, 2004.</citation>
  </reference>
  <reference>
    <citation>Owen JB, Grigsby PW, Caldwell TM, Konski AA, Johnson DJ, Demas WF, Movsas B, Jones CU, Wasserman TH. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):633-9.</citation>
    <PMID>11172943</PMID>
  </reference>
  <reference>
    <citation>Owen J, Grigsby P, Caldwell T, et al.: Can costs be measured and predicted by modelling within a cooperative clinical trials group? Economic methodological pilot studies of Radiation Therapy Oncology Group studies 9003 and 9104. [Abstract] Int J Radiat Oncol Biol Phys 45 (3 suppl): A-150, 225, 1999.</citation>
  </reference>
  <results_reference>
    <citation>Chung CH, Dignam JJ, Hammond ME, Klimowicz AC, Petrillo SK, Magliocco A, Jordan R, Trotti A, Spencer S, Cooper JS, Le QT, Ang KK. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011 Apr 1;29(10):1326-34. doi: 10.1200/JCO.2010.32.3295. Epub 2011 Feb 28.</citation>
    <PMID>21357786</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung CH, Dignam J, Hammond ME, et al.: Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003). [Abstract] J Clin Oncol 28 (Suppl 15): A-5552, 2010.</citation>
  </results_reference>
  <results_reference>
    <citation>Konski AA, Winter K, Cole BF, Ang KK, Fu KK. Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Head Neck. 2009 Feb;31(2):207-12. doi: 10.1002/hed.20949.</citation>
    <PMID>19107946</PMID>
  </results_reference>
  <results_reference>
    <citation>Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol. 2009 Sep 10;27(26):4281-6. doi: 10.1200/JCO.2008.20.6003. Epub 2009 Aug 10.</citation>
    <PMID>19667273</PMID>
  </results_reference>
  <results_reference>
    <citation>Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK; Radiation Therapy Oncology Group 90-03 Trial. Microvessel density &gt;or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol. 2007 Aug;30(4):406-19.</citation>
    <PMID>17762442</PMID>
  </results_reference>
  <results_reference>
    <citation>Konski AA, Bhargavan M, Owen J, et al.: Altered fractionated radiotherapy is cost-effective in the treatment of locally advanced head and neck cancer: an economic analysis of Radiation Therapy Oncology Group (RTOG) 90-03. [Abstract] J Clin Oncol 24 (Suppl 18): A-6007, 302s, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, Cooper JS; Radiation Therapy Oncology Group. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head Neck. 2006 Apr;28(4):287-96.</citation>
    <PMID>16287132</PMID>
  </results_reference>
  <results_reference>
    <citation>Pajak TF, Trotti A, Gwede CK, et al.: The TAME risk classification system: acute toxicity burden and IPD analysis of RTOG 90-03. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-217, S131, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Trotti A, Fu KK, Pajak TF, et al.: Long term outcomes of RTOG 90-03: a comparison of hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-116, S70, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Hammond E, Berkey BA, Fu KK, Trotti A, Meredith RF, Jones CU, Byhardt R, Horwitz EM, Ang KK. P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):683-92.</citation>
    <PMID>14529772</PMID>
  </results_reference>
  <results_reference>
    <citation>Konski A, Berkey BA, Kian Ang K, Fu KK. Effect of education level on outcome of patients treated on Radiation Therapy Oncology Group Protocol 90-03. Cancer. 2003 Oct 1;98(7):1497-503.</citation>
    <PMID>14508838</PMID>
  </results_reference>
  <results_reference>
    <citation>Tu X, Berkey BA, Zhang HZ, et al.: Impact of EGFR expression on the response of advanced head and neck carcinomas to concomitant boost radiotherapy in a RTOG phase III trial (90-03). Int J Radiat Oncol Biol Phys 57 (2 Suppl): S157, 2003.</citation>
  </results_reference>
  <results_reference>
    <citation>Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002 Dec 15;62(24):7350-6.</citation>
    <PMID>12499279</PMID>
  </results_reference>
  <results_reference>
    <citation>Eldridge B, Rabinovitch R, Berkey BA, et al.: The impact of baseline nutritional support on treatment outcome in patients with locally advanced squamous cell cancer of the head and neck treated with definitive radiotherapy: report of the Radiation Therapy Oncology Group (RTOG) trial 90-03. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-199, 115, 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>Konski A, Berkey B, Ang KK, et al.: The effect of education level on outcome of patients treated on Radiation Therapy Oncology Group (RTOG) protocol 90-03. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-992, 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>Calvin DP, Hammond ME, Pajak TF, et al.: Microvessel density (MVD)&gt; 60 does not predict for outcome in advanced head and neck squamous cell carcinoma (HNSCC): results of a prospective study from the RTOG 90-03 trial. [Abstract] Int J Radiat Oncol Biol Phys 51 (3 suppl 1): A-68, 41, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>Fisher J, Scott C, Fu K, et al.: Treatment, patient and tumor characteristics impact quality of life (QOL) in patients with locally advanced head and neck cancer: report of the Radiation Therapy Oncology Group (RTOG) trial 90-03. [Abstract] Int J Radiat Oncol Biol Phys 51 (3 suppl 1): A-174, 98, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>Konski AA, Scott CB, Ang KK, et al.: Does dose escalation of radiotherapy (RT) improve quality-adjusted survival (QAS) in unresectable head and neck cancer (HNC) patients (Pts)? Radiation Therapy Oncology Group (RTOG) study 90-03. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-906, 227a, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>Konski A, Scott C, Ang KK, et al.: Cost-utility analysis of RTOG 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-87, 48, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>Fisher J, Scott C, Fu K, et al.: Randomized study comparing quality of life between standard fractionation radiotherapy and altered fractionation schemas in patients with locally advanced squamous cell cancer of the head and neck. [Abstract] Proceedings of the International Conference on Head and Neck Cancer A201, 117, 2000.</citation>
  </results_reference>
  <results_reference>
    <citation>Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16.</citation>
    <PMID>10924966</PMID>
  </results_reference>
  <results_reference>
    <citation>Hammond E, Pajak T, Fu K, et al.: p105 as a prognostic indicator in patients irradiated for locally advanced head and neck cancer: a clinical/laboratory correlative analysis of RTOG 9003. [Abstract] Proceedings of the International Conference on Head and Neck Cancer A135, 145, 2000.</citation>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

